One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney ...

Realistically, there’s a good chance your patients are using them to get GLP-1 agonists. And sometimes ... care process is the best course of action. We shouldn’t let a patient start with ...

With promising therapeutic effects comes an increased scrutiny on side effects. GLP-1 receptor agonists mimic the action of the native GLP-1 peptide, enhancing insulin secretion, suppressing glucagon ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

The research found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 ...